Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy

Sleep Medicine

Volumn 1, Issue 3, 2000, Pages 231-243

  Mitler, Merrill M ^a   Harsh, John ^b   Hirshkowitz, Max ^c   Guilleminault, Christian ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Sleep Disorders Center   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

Disorders of excessive somnolence; Modafinil; Narcolepsy; Quality of life; Sleep disorders; Wakefulness

Indexed keywords

EID: 0001609188     PISSN: 13899457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1389-9457(00)00031-9     Document Type: Article

References (29)

1. Hublin C., Partinen M., Kaprio J., Koskenvuo M., et al. Epidemiology of narcolepsy. Sleep. 17:1994;S7-S12.
2. Guilleminault C., Mignot E., Grumet F.C. Familial patterns of narcolepsy. Lancet. 2:1989;1376-1379.
3. Mignot E., Lin X., Arrigoni J., Macaubas C., et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and Black Americans. Sleep. 17:1994;S60-S67.
4. Broughton R., Ghanem Q., Hishikawa Y., Sugita Y., et al. Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can J Neurol Sci. 8:1981;299-304.
5. Kales A., Soldatos C.R., Bixler E.O., Caldwell A., et al. Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology. Arch Neurol. 39:1982;169-171.
6. Green P.M., Stillman M.J. Narcolepsy. Signs, symptoms, differential diagnosis, and management. Arch Fam Med. 7:1998;472-478.
7. Guilleminault C. Narcolepsy syndrome. Kryger M.N., Roth T., Dement W.C. Principles and practice of sleep medicine. 1994;549-561 W.B. Saunders, Philadelphia, PA.
8. Mitler M.M., Aldrich M.S., Koob G.F., Zarcone V.P. Narcolepsy and its treatment with stimulants. ASDA standards of practice. Sleep. 17:1994;352-371.
9. Hoffman B.B., Lefkowitz R.J. Carecholamines. sympthathomimetic drugs, and adrenergenic receptor antogonists. Hardman J.G., Limbird L.E., Molinoff P.B., Ruddon R.W., Gilman A.G. Goodman & Gilman's the pharmacologic basis of therapeutics. 9th ed :1996;199-248 McGraw-Hill, New York.
10. Parkes J.D., Guilleminault C., Dement W.C., Pasouant P. Narcolepsy. 1976;644-658 Spectrum, New York.
11. Modafinil U.S. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol. 43:1998;88-97.
12. Modafinil U.S. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 54:2000;1166-1175.
13. Carskadon M.A., Dement W.C., Mitler M.M., Roth T., et al. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep. 9:1986;519-524.
14. Mitler M.M., Gujavarty K.S., Browman C.P. Maintenance of wakefulness test: a polysomnographic technique for evaluation treatment efficacy in patients with excessive somnolence. Electroenceph clin Neurophysiol. 53:1982;658-661.
15. Guy W. ECDEU assessment manual for psychopharmacology. 1976;National Institute of Mental Health, US Department of Health, Education, and Welfare, Washington, DC.
16. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 14:1991;540-545.
17. Narcolepsy. The International classification of sleep disorders diagnostic and coding manual. Rochester: American Sleep Disorders Association, 1990. pp. 38-49.
18. Ware J.E. SF-36 health survey. Manual and interpretation guide. 1993;The Health Institute, New England Medical Center, Boston, MA.
19. McHorney C.A., Ware J.E., Lu J.F.R., Sherbourne C.D. The MOS 36-item short-form health survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 32:1994;40-66.
20. McHorney C.A., Ware J.E., Raczek A.E. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical test of validity in measuring physical and mental health constructs. Med Care. 31:1993;247-263.
21. Aloe F., Pedroso A., Tavares S.M. Epworth Sleepiness Scale outcome in 616 Brazilian medical students. Arq Neuropsiquiatr. 55:1997;220-226.
22. Whitney C.W., Enright P.L., Newman A.B., Bonekat W., et al. Correlates of daytime sleepiness in 4578 elderly persons: the Cardiovascular Health Study. Sleep. 21:1998;27-36.
23. Maycock G. Sleepiness and driving: the experience of heavy goods vehicle drivers in the UK. J Sleep Res. 6:1997;238-244.
24. Johns M., Hocking B. Daytime sleepiness and sleep habits of Australian workers. Sleep. 20:1997;844-849.
25. Beusterien K.M., Rogers A.E., Walsleben J.A., Emsellem H.A., et al. Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep. 22:1999;757-765.
26. Solomon G.D., Skobieranda F.G., Genzen J.R. Quality of life assessment among migraine patients treated with sumatriptan. Headache. 35:1995;449-454.
27. Beusterien K.M., Nissenson A.R., Port F.K., Kelly M., et al. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol. 7:1996;763-773.
28. Make B., Glenn K., Ikle D., Bucher B., et al. Pulmonary rehabilitation improves the quality of life of subjects with chronic obstructive pulmonary disease (COPD). Am Rev Respir Dis. 145:1992;A767.
29. PROVIGIL® (modafinil) Package Insert. March 1999. Cephalon, Inc., West Chester, PA. Available at: http://www.provigil.com.